Drug Profile
Influenza A virus H7N9 vaccine - EpiVax
Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator EpiVax
- Developer EpiVax; Flinders University; Vaxine
- Class Influenza A virus H7N9 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H7N9 subtype
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for phase-I development in Influenza-A virus H7N9 subtype in USA (Parenteral)
- 28 Mar 2022 No recent reports of development identified for research development in Influenza-A virus H7N9 subtype(Prevention) in USA (Parenteral)
- 09 Mar 2020 Phase I development is ongoing in USA (EpiVax pipeline, March 2020)